CapForce IBD 50 ETF
Data updated: 2026-09-21
C000272876 — CapForce IBD 50 ETF. United States Mid Cap Growth Equity · $79.53M AUM · 0.80% expense ratio. Holdings, fees, performance and SEC filings.
C000272876 Fund Overview
CapForce IBD 50 ETF is a US ETF managed by Capital Force ETF Trust, categorised as United States Mid Cap Growth Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Capital Force ETF Trust
- Category: United States Mid Cap Growth Equity
- Assets under management: $79.53M
- SEC CIK: 0002104659
- SEC series ID: S000102391
- Share class ID: C000272876
C000272876 Investment Objective and Strategy
CapForce IBD 50 ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Capital Force ETF Trust.
Investment objective
The Fund seeks to track, before fees and expenses, the performance of the IBD O 50 Index (the Index ).
Principal investment strategy
The Fund will normally invest at least 80% of its net assets (including investment borrowings) in securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Funds investment sub-adviser, Penserra Capital Management LLC (Penserra or the Sub-Adviser ), seeks to achieve a high degree of correlation with the Index in order to minimize tracking error, which is the variation between the Funds annual return and the return of the Index. The Index is a weekly, rules-based, computer-generated stock index compiled and published by Investors Business Daily (IBD or the Index Provider) that seeks to identify the current top 50 growth stocks. The equity portion of the Index primarily includes U.S.
common stocks, but may, to a lesser extent, include common stocks of non-U.S. companies that utilize American Depositary Receipts (ADRs) to trade on U.S. securities exchanges. The equity securities comprising the Index may be issued by small-, mid- and large-capitalization companies located in either developed or emerging markets. The Index may incorporate a cash equivalents position when fewer than 50 stocks meet the Indexs selection criteria, which typically occurs during periods of market weakness . The Indexs initial universe of the approximately 7,000 equity securities that trade on the New York Stock Exchange, The Nasdaq Stock Market, LLC or NYSE American LLC is initially narrowed down by excluding those companies that do not meet certain baseline criteria. These criteria include minimum stock price, minimum trading volume, minimum upward price movement and minimum simple price moving average.
IBD then narrows the universe further by screening out securities with price actions IBD views as undesirable. For instance, IBD removes securities with excessive price percentage moves in its 10-week price moving average (6% or more), securities with a high number of positive price movement days over a 14-day period (seven or more), securities with a high number of positive price movement weeks over an 8-week period (six or more) and/or securities with a high number of consecutive positive price movement weeks (three or more). These criteria are explained in detail in Index Information. IBD then evaluates and scores the remaining securities on the below 11 factors. The first five factors comprise the base score for a security using a proprietary weighting of the following proprietary ratings published by IBD: Earnings Per Share Rating; Relative Price Strength Rating; Sales Margin Return on Equity Rating; Accumulation Distribution Rating; and Industry Group Relative Strength Rating.
The next six metrics add to or subtract from the base score to derive the final aggregate score, and are: Growth in quarterly earnings per share and next quarter consensus estimates; 3-to-5 year annual earnings per share growth rate and next fiscal years consensus estimates; Quarterly sales growth and next quarter consensus estimates; Acceleration in quarterly sales or earnings growth rates; Liquidity measured by share price and 50-day average daily trading volume; and Annual return on equity metrics from the companys income statement. These factors are also explained in detail in Index Information. Each security is given a score for each factor. Each securitys 11 factor scores are then aggregated to provide a composite score. The 50 securities with the highest score are included in the Index and weighted according to their score.
Securities with the ten highest scores are given a weight of 3.5%. Securities with the 11th-20th highest scores are given a weight of 3.0%. Securities with the 21st-30th highest scores are given a weight of 2.0%. Securities with the 31st-40th highest scores are given a weight of 1.0% and securities with the 41st-50th highest scores are given a weight of 0.5%. The Fund generally invests in all of the securities comprising the Index in proportion to the weightings of the securities in the Index. The Index is rebalanced and reconstituted weekly. This weekly rebalancing and reconstituting of the Index will cause the Fund to have a higher portfolio turnover rate than similar funds. The Fund is classified as a diversified company under the 1940 Act. To the extent the Index concentrates (i.e., holds 25% or more of its total assets) in the securities of a particular industry or group of industries, the Fund will concentrate its investments to the same extent.
As of the date of this prospectus, the Fund has significant exposure to the information technology sector.
C000272876 Holdings
Top 10 holdings of CapForce IBD 50 ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Kiniksa Pharmaceuticals Intern | 4.24% |
| Guardant Health Inc | 3.83% |
| Travere Therapeutics Inc | 3.54% |
| TG Therapeutics Inc | 3.52% |
| Enova International Inc | 3.49% |
| Liquidia Corp | 3.44% |
| Okeanis Eco Tankers Corp | 3.26% |
| Oscar Health Inc | 3.23% |
| Sezzle Inc | 3.16% |
| Carpenter Technology Corp | 3.15% |
C000272876 Portfolio Allocation
Asset-class allocation of CapForce IBD 50 ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 0.2% |
C000272876 Performance
Total returns for C000272876 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 14.3% |
C000272876 Costs and Fees
C000272876 costs about $80 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.80%
- Gross expense ratio: 1.00%
- Portfolio turnover: 1209%
C000272876 Cashflows
Over the 12 months to 2026-04, CapForce IBD 50 ETF had net inflows of $0, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $0 |
C000272876 Debt Constituents
No individual debt constituents are reported in CapForce IBD 50 ETF's latest SEC N-PORT filing.
C000272876 Prospectus and SEC Filings
Official CapForce IBD 50 ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Mid Cap Growth Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.